ImmunXperts

What ImmunXperts does

ImmunXperts is a Belgian specialty contract research organization headquartered in Gosselies, Belgium, founded in 2014, that provides in vitro immunology testing services to pharmaceutical and biotechnology companies developing biologics, monoclonal and bispecific antibodies, cell and gene therapy products, novel anti-oncolytic molecules, small molecules, and generic peptides. The lab's core portfolio centers on immunogenicity risk assessment — the prediction and characterization of anti-drug antibody responses — using T-cell activation and proliferation as surrogate markers, cytokine release assays, and MHC-associated peptide proteomics (MAPPS), alongside functional screening of immuno-oncology and cell/gene therapy candidates. The company also maintains a PBMC biobank of more than 1,300 healthy donors with 4-digit HLA typing under a Belgian Biobank License, enabling population-diverse clinical trial simulation; consultative protocol review, theoretical immunology courses, and hands-on training are offered as adjacent service lines.

Name

ImmunXperts

Legal name

ImmunXperts

Website

https://immunxperts.com

Company type

Private

Founded year

2014

Operating status

Acquired

Headcount range

11–50 employees

Short description

ImmunXperts, now part of IQVIA's Discovery Sciences division, is a Belgian in vitro immunology CRO providing immunogenicity risk assessment, T-cell and cytokine release assays, MAPPS, and PBMC biobank services to pharmaceutical and biotech clients developing biologics, cell therapies, and immuno-oncology products.

Ownership category

akta.pro rank

Product category

Preclinical Immunology Laboratory Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151), Medical and Diagnostic Laboratories (6215), Testing Laboratories and Services (541380)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071), Services-Testing Laboratories (8734)

akta.pro primary industry

Immunotoxicology & Immunogenicity Assessment (HLAGAFAH)

akta.pro secondary industries

Immuno-Oncology & Immune Monitoring Biomarkers (TMB, MSI, MRD, immune profiling) (HLAAAMAK), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB), Cell-Based & Potency Assays (Bioassays) (HLAGADAH)

Keywords

• Immunogenicity risk assessment
• In vitro immunology services
• Immuno-oncology testing
• T-cell activation assays
• PBMC biobank services

Headquarters

HQ city

Gosselies

HQ country

Belgium

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Laboratory Testing Services: Contract laboratory services providing immunogenicity risk assessment and functional screening assays for biopharmaceutical clients. Revenue derived from testing fees for discovery through pre-IND stage programs.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

ImmunXperts provides contract in vitro immunology testing services focused on immunogenicity risk assessment and immuno-oncology, including T-cell activation and proliferation assays, cytokine release assays, and MHC-associated peptide proteomics (MAPPS). The Gosselies, Belgium-based lab operates a Belgian-licensed PBMC biobank with samples from more than 1,300 healthy donors with 4-digit HLA typing, and supports pharmaceutical and biotech clients developing biologics, monoclonal antibodies, bispecific antibodies, cell and gene therapies, and novel anti-oncolytic molecules from discovery through pre-IND stages.

Product overview

IQVIA's In Vitro Immunology laboratory (formerly ImmunXperts) is a specialized contract research organization providing immunogenicity risk assessment and functional screening services for biotherapeutics. The offering is organized around a core portfolio of laboratory services including T-cell activation assays, cytokine release assays, and MAPPS (MHC-associated peptide proteomics), supplemented by a high-quality PBMC biobank with over 1300 donors and consultative training services. Located in Gosselies, Belgium, the lab assists clients in advancing programs from discovery through pre-IND and exploratory clinical stages.

Differentiator

Problem solved

Functional benefit

Products and services

• Immunogenicity Risk Assessment Services Contract laboratory service that uses in silico and in vitro methods to evaluate the potential for anti-drug antibody formation in biologic and novel therapeutic candidates, intended for pharmaceutical and biotech sponsors.
• T-cell Activation and Proliferation Assays In vitro assays using T-cell activation and proliferation as surrogate markers for the induction of anti-drug antibodies, providing functional insights into immune-mediated adverse events for biotherapeutic developers.
• Cytokine Release Assays In vitro assays that assess cytokine release as a measure of immune activation and potential adverse events for drug candidates in development.
• MHC-associated Peptide Proteomics (MAPPS) Proteomics service identifying and characterizing peptide fragments presented by major histocompatibility complex molecules to support immunogenicity evaluation of biotherapeutics.
• Functional Screening Assays for Immuno-oncology Functional screening assays for drug candidates in immuno-oncology, cell and gene therapy, and other disease areas, supporting developers of novel therapeutics.
• PBMC Biobank Services Storage and provision of high-quality PBMC samples from more than 1,300 healthy donors with 4-digit HLA typing under a Belgian Biobank License, supporting diverse population representation for clinical trial simulation and immunology studies.
• Antibody and New Modality Services Immunogenicity and functional testing services supporting novel anti-oncolytic molecules, monoclonal antibodies, bispecific antibodies, new antibody formats, small molecules, and generic peptides.

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• IQVIAcoreOthersImmunXperts was acquired and integrated into IQVIA's Discovery Sciences division as their In Vitro Immunology lab team. The team now operates under IQVIA's corporate structure while maintaining specialized immunology testing capabilities. This represents a significant integration where ImmunXperts' expertise became part of IQVIA's broader laboratory services offering.

Scale indicators1 record

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Lonza: Provides cell and gene therapy manufacturing services alongside bioassay and immunogenicity testing for biologics developers. Comparable in supporting novel-modality immunology workflows, with a much larger biologics manufacturing footprint.
• Eurofins Scientific: Bioanalytical testing network with extensive immunology, immunogenicity, and biomarker assay capabilities across pharma services. Comparable as a scaled alternative for the same biopharma buyer set ImmunXperts serves.
• Labcorp Drug Development (Fortrea): Global CRO offering immunogenicity, bioanalytical, and central lab services for biologics and cell/gene therapy programs. Comparable in service scope to ImmunXperts, with substantially broader geographic footprint and program capacity.
• WuXi AppTec (WuXi Biologics / WuXi STA): Global CRO/CDMO offering biologics discovery, immunology, and bioassay services. Comparable in offering immunogenicity and cell-based functional assays, with significantly broader China-based capacity.
• Charles River Laboratories: Large preclinical CRO with broad immunogenicity, bioanalytical, and cell-based assay services across the discovery-to-IND continuum. Directly comparable to ImmunXperts' in vitro immunology offering, but at much greater scale and as part of a wider safety/CMO portfolio.

Others

• Sartorius: Supplies bioprocessing and cell-line engineering tools used by biologics and cell-therapy developers, with adjacent analytical and cell-based assay capabilities. Comparable as an adjacent ecosystem participant that cell/gene therapy customers of ImmunXperts also engage.

Emerging players

• CellGenix: Supplier of raw materials and testing/QC services for cell and gene therapy developers. Comparable in serving cell/gene therapy customers that require immunology-relevant characterization, with focused cell-therapy expertise.
• ReachBio Research Labs: Specialized cell-based assay CRO offering functional immunology, cytokine, and hematopoietic assays for pharma research. Comparable niche overlap with ImmunXperts' functional screening offerings, at a smaller, emerging-player scale.

Direct peers

• ProImmune: Specialized provider of MHC-associated peptide proteomics (MAPPS), immunogenicity, and immune-monitoring services. Most directly comparable peer to ImmunXperts on MAPPS and T-cell assay offerings, both serving biopharma R&D.
• Abzena: Contract development organization focused on biologics and antibody-drug conjugates, including immunogenicity and bioassay services. Comparable in serving biologic developers needing immunogenicity risk assessment, with broader antibody development capability.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/immunxperts
• LinkedInlinkedin.com/company/immunxperts

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ImmunXperts